Royalty Pharma plc (RPRX) | Stock Overview & Key Data
Royalty Pharma plc Performance Comparison
Stock Range
Today's Range
Low: $36.15
High: $36.60
on October 2, 2025
52 Week Range
Low: $24.05
High: $38.00
on December 19, 2024
on August 5, 2025
All-Time High: $56.50 on June 15, 2020
Explore how other US stocks compare to their 52-week ranges: View US Market 52-Week Insights
Key Statistics
Market Cap
$21.0B
EPS
2.31
P/E Ratio (TTM)
15.44
Forward P/E
8.12
P/B Ratio
2.43
PEG Ratio
-0.22
Div. Yield
3.03%
ROE
17.29%
Beta
0.574
Debt to Equity
84.43
Financial Highlights
Profitability
Gross Margin
N/A
Operating Margin
38.85%
Profit Margin
44.28%
Returns and Earnings
Return on Assets (TTM)
6.49%
Return on Equity (TTM)
17.29%
EBITDA
$1.9B
Net Income (TTM)
$1.0B
Growth
Revenue (TTM)
Revenue Per Share (TTM)
$5.17
Quarterly Revenue Growth (YoY)
7.70%
Quarterly Earnings Growth (YoY)
-70.40%
Dividend Information
Last 12-Month Dividend
$1.08
Current Dividend Yield
3.03%
3-Year Average Dividend Yield
0.64%
3-Year Average Annual Dividend
$0.89
3-Year Total Dividends
$2.68
Ex-Dividend Date
August 15, 2025
Peer Performance Comparison
| Company | Market Cap | 1W | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y |
|---|---|---|---|---|---|---|---|---|---|
| Royalty Pharma plc RPRX | 21.04B Large-cap | 4.56% | 0.88% | 0.83% | 16.66% | 41.49% | 31.50% | -10.70% | -17.22% |
| Vertex VRTX | 100.41B Large-cap | 7.07% | 1.96% | -10.54% | -15.44% | 0.76% | -10.20% | 38.49% | 51.45% |
| Alnylam ALNY | 60.43B Large-cap | 2.54% | 3.13% | 39.79% | 72.77% | 97.32% | 72.02% | 135.43% | 213.60% |
| Regeneron REGN | 59.93B Large-cap | 8.01% | 3.82% | 9.54% | -4.09% | -16.11% | -40.76% | -16.94% | -0.34% |
| Insmed INSM | 29.94B Large-cap | 12.69% | 5.16% | 55.54% | 108.06% | 118.44% | 111.43% | 591.72% | 323.86% |
| Incyte INCY | 16.38B Large-cap | 5.66% | 0.35% | 26.57% | 38.42% | 24.09% | 27.84% | 26.10% | -9.88% |
Ownership & Short Interest
Insider Ownership
8.73%
Institutional Ownership
82.62%
Shares Short
21M
Short Ratio
5.37
Short % of Shares Outstanding
5.00%
Average 10-Day Volume
6M
Average 90-Day Volume
5M
Recurring Investment / Dollar-Cost Averaging Calculator
Calculate how a regular investment in would have performed over time.
Note: This calculator is for informational purposes only and does not consider taxes, fees, or other costs associated with investing.
Frequently Asked Questions
- What is RPRX's 52-week high and low?
- In the last 52 weeks, Royalty Pharma plc reached a high of $38.00 (on August 5, 2025) and a low of $24.05 (on December 19, 2024).
- What is the market cap and P/E ratio for RPRX?
- Curious about Royalty Pharma plc's size and valuation? Its market capitalization stands at 21.04B. When it comes to valuation, the P/E ratio (trailing twelve months) is 15.44, and the forward P/E (looking ahead) is 8.12.
- Does RPRX pay dividends? If so, what's the yield?
- Yes, Royalty Pharma plc is a dividend-paying stock. Investors have recently enjoyed a trailing annual dividend yield of 3.03%, and the company has paid an average of $0.89 per share annually over the past 3 years.
- Who are Royalty Pharma plc's main competitors or similar companies to consider before investing?
When looking at Royalty Pharma plc, it can be helpful to see how it compares to other players in its field. Here are a few similar companies or key competitors:
Company Mkt Cap Sector Industry 1Y Return 3Y Return Vertex
VRTX100.41B Healthcare Biotechnology -10.20% 38.49% Alnylam
ALNY60.43B Healthcare Biotechnology 72.02% 135.43% Regeneron
REGN59.93B Healthcare Biotechnology -40.76% -16.94% Insmed
INSM29.94B Healthcare Biotechnology 111.43% 591.72% Incyte
INCY16.38B Healthcare Biotechnology 27.84% 26.10% For a more comprehensive list, please see the Peer Performance Comparison table on this page.
- What are the key financial health indicators for Royalty Pharma plc? (e.g., ROE, Debt/Equity)
- To get a sense of Royalty Pharma plc's financial health, here are a few key indicators: its Return on Equity (ROE) over the last twelve months is 17.29%, the Debt to Equity ratio from the most recent quarter is 84.43, and its Gross Profit Margin stands at N/A.
- What is the recent revenue and earnings growth for RPRX?
- Looking at Royalty Pharma plc's growth, its revenue over the trailing twelve months (TTM) was $2B. Compared to the same quarter last year (YoY), quarterly revenue grew by 7.70%, and quarterly earnings saw a YoY growth of -70.40%.
- How much of RPRX stock is held by insiders and institutions?
- Wondering who owns Royalty Pharma plc stock? Company insiders (like executives and directors) hold about 8.73% of the shares, while institutional investors (such as mutual funds and pension funds) own approximately 82.62%.
For more common questions about our data, please visit our About Data page.
Data is provided for informational purposes only. Devyara does not guarantee the accuracy of the data displayed.